Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Discovery Labs Appoints John R. Leone to Board of Directors



         Discovery Labs Appoints John R. Leone to Board of Directors

PR Newswire

WARRINGTON, Pa., Nov. 14, 2012

WARRINGTON, Pa., Nov. 14, 2012 /PRNewswire/ -- Discovery Laboratories, Inc.
(Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new
standard in respiratory critical care, today announced it has appointed John
R. Leone to the Company's Board of Directors, effective immediately.

"With over three decades of experience and an outstanding track record in
pharmaceutical operations, commercial portfolio management, and financing life
science companies, John's expertise will be invaluable to our Board," said W.
Thomas Amick, Chairman of the Board and Chief Executive Offer at Discovery
Labs, "As we prepare for the commercial launch of SURFAXIN^® and continue the
development of AEROSURF^® and SURFAXIN LS™, John will bring an important
perspective in guiding the business and financial strategies we employ as we
build our Company."

Since 2007, Mr. Leone has been a Partner at Paul Capital Healthcare, a leading
private equity firm that manages one of the largest dedicated healthcare funds
globally.  At Paul Capital, Mr. Leone has focused on investment opportunities
in commercial-stage life science companies.  From 2004 to 2006, Mr. Leone was
President and Chief Executive Officer at Cambrex Corporation, a
publicly-traded life sciences company providing innovative solutions that
accelerate the development and commercialization of pharmaceutical products.
 Previously, Mr. Leone served as Senior Vice President and Chief Operating
Officer of U.S. Commercial Operations at Aventis Pharmaceuticals.  In this
position he had responsibility for all commercial business units, including
oncology, metabolism, cardiovascular, dermatology, respiratory and
anti-infective.  Mr. Leone played a key role in spearheading the successful
integration of its predecessor companies, Rhone-Poulenc Rorer and Hoechst
Marion Roussel, to form Aventis.

"I am excited to join the Board to help guide and provide strategic input at
this important juncture for the Company." said John R. Leone, "I am impressed
with Discovery Labs' KL4 surfactant and aerosol delivery technologies and
believe they have the potential to advance a new standard in respiratory
critical care, beginning by addressing the unmet needs of premature infants at
risk for respiratory distress syndrome (RDS).  I look forward to being a part
of that change."

Mr. Leone's commercial experience also includes significant domestic and
international executive management roles with Wyeth, where he held the
following positions during his tenure: General Manager, Ayerst International;
General Manager of commercial operations for Ayerst U.S.; Group Vice President
of Wyeth International Marketing and General Manager, Vaccine and Pediatric
Division.  Mr. Leone started his healthcare career at Pfizer Laboratories,
where he held various senior marketing positions in both the U.S. and
International groups and was responsible for the commercial launch of numerous
pharmaceutical products.

Mr. Leone also serves on the Board of Directors at ViroPharma Incorporated. 
Mr. Leone received his BS degree in Engineering from the U.S. Military Academy
at West Point and his MBA from the University of Colorado.

ABOUT DISCOVERY LABS
Discovery Laboratories, Inc. is a specialty biotechnology company with one
focus – to advance a new standard in respiratory critical care.  Discovery
Labs' novel proprietary KL4 surfactant technology produces a synthetic,
peptide-containing surfactant that is structurally similar to pulmonary
surfactant and is being developed in liquid, lyophilized, and aerosolized
dosage forms. Discovery Labs is also developing its proprietary drug delivery
technologies to enable efficient delivery of aerosolized KL4 surfactant and
other inhaled therapies. Discovery Labs believes that its proprietary
technologies make it possible, for the first time, to develop a significant
pipeline of products to address a variety of respiratory diseases for which
there frequently are few or no approved therapies.  For more information,
please visit our website at www.Discoverylabs.com.

Forward-Looking Statements
To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995.  These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from the
statements made.  Examples of such risks and uncertainties, including those
related to the potential commercial introduction of SURFAXIN and AFECTAIR and
Discovery Labs' research and development programs are described in Discovery
Labs' filings with the Securities and Exchange Commission, including the most
recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.

SOURCE Discovery Laboratories, Inc.

Website: http://www.discoverylabs.com
Contact: Media Relations: Michael Parks, Pitch360, +1-484-356-7105,
Michael@pitch360inc.com; Investor Relations: Mike Rice, LifeSci Advisors,
+1-646-597-6979; John G. Cooper, President and Chief Financial Officer,
+1-215-488-9490
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement